Hematopoietic SCT (HSCT) is often complicated by viral reactivations. In this retrospective cohort study (January 2004-August 2008, predictors for human herpes virus 6 (HHV6)-reactivation and associations between HHV6-reactivation and clinical outcomes after allogeneic HSCT were studied. HHV6 DNA load in plasma was monitored weekly by quantitative real-time PCR. Associations between the main end point HHV6-reactivation and other end points, that is, acute GVHD (aGVHD) and NRM were analyzed using Cox proportional hazard models. In total, 108 patients receiving either a myeloablative (MA; n ¼ 60) or non-myeloablative (NMA; n ¼ 48) conditioning regimen were included. Median age was 40 years (range 17-65); median follow-up was 20 months (range 3-36). In 16/60 (27%) patients with MA conditioning regimen, a HHV6 reactivation was observed (mean viral load 50 323 cp/mL) compared with 2/48 (4%) patients with a NMA conditioning regimen with low viral load (mean 1100 cp/mL). In multivariate analysis, MA conditioning was the only predictor for HHV6 reactivation (P ¼ 0.02). In addition, HHV6 reactivation was associated with grades 2-4 aGVHD (Po0.001) and NRM (P ¼ 0.03). Regular monitoring of HHV6 reactivation after HSCT might be important in MA HSCT patients to enable early initiation of antiviral treatment or to anticipate aGVHD, all of which may improve clinical outcome.
INTRODUCTION
Viral reactivations are major complications after allogeneic hematopoietic SCT (HSCT). The compromised immune system in allogeneic HSCT recipients due to the administration of serotherapy (for example, antithymocyte globulin) and immunosuppressive drugs to prevent acute GVHD (aGVHD) and rejection of the donor graft may increase the risk of viral reactivations.
Herpes virus reactivations, like human CMV (HCMV) and EBV, have been described to be associated with aGVHD, allograft rejections and increased NRM. [1] [2] [3] Human herpes virus 6 (HHV6), which reactivates early after HSCT, was found to be associated with aGVHD and increased NRM in children and, recently, in adults. [4] [5] [6] [7] Predictors for the development of HHV6 reactivation are largely unknown. To date, only broad-spectrum and relatively toxic antiherpes virus drugs (for example, (val)ganciclovir and foscarnet-sodium) are used in the treatment of HHV6 disease or -reactivation. 8, 9 With the progress in molecular diagnostics, better monitoring allows for further elucidation of the role of HHV6 reactivation and therapeutic protocols after HSCT. Therefore, we studied the predictors for HHV6 reactivation and the association of HHV6 reactivation with clinical outcome in adult allogeneic-HSCT recipients.
PATIENTS AND METHODS
A retrospective study was performed in the University Medical Center Utrecht and the Erasmus Medical Center Rotterdam (Erasmus MC) in the Netherlands between January 2004 and May 2008. Adults receiving a first allogeneic myeloablative (MA) HSCT and consecutive cohort of nonmyeloablative (NMA)-treated HSCT patients was also included in both centers. Transplantation characteristics as well as transplantation-associated morbidity (for example, aGVHD, chronic GVHD (cGVHD) and other viral reactivations) were registered. Patients were enrolled in the HSCT research protocol after providing written informed consent. The study was approved by the Ethics Committee of the University Medical Center Utrecht.
Conditioning regimens, supportive care and treatment NMA conditioning regimen. Patients were selected for an NMA conditioning regimen based on age (o40 years) and pre-HSCT comorbidity. For patients with a matched related donor, the conditioning regimen consisted of fludarabin (30 mg/m 2 per day i.v. for 3 days, Bayer, Leverkusen, Germany) and low-dose TBI (200 cGy). In case of an HLAmismatched donor, antithymocyte globulin (thymoglobulin 2 mg/kg per day for 4 days, Genzyme, Cambridge, MA, USA) was added to the regimen. Patients with multiple myeloma, within 3 months after high-dose melphalan (200 mg/m Supportive care. Patients received anti-emetic drugs and prophylactic anticonvulsive therapy (diphantoine 300 mg daily) during BU administration. Ciprofloxin (1000 mg i.v. daily) and fluconazol (150 mg daily) were administered from the start of MA medication until the end of the neutropenic period (defined as o500 neutrophils/mL). Cefazoline (3000 mg i.v. daily) was added from day þ 1 until day þ 12 after HSCT.
Immunosuppression after HSCT. CsA (dose adjusted to plasma levels 200-400 mg/L) and 45 mg/kg mycophenolate mofetil was given to all patients as GVHD prophylaxis. Mycophenolate mofetil was administered until day þ 84 and CsA was tapered at day þ 120 after HSCT, if no GVHD was present.
aGVHD and cGVHD. aGVHD was diagnosed and graded according to the Glucksberg criteria, 10 and grade 41 aGVHD was treated with prednisone 2 mg/kg per day and CsA, and mycophenolate mofetil doses were increased or continued. cGVHD was graded according to the Seattle classification.
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Limited cGVHD was treated with topical steroids, whereas extensive cGVHD was treated with oral prednisone treatment (1 mg/kg per day).
Viral-load monitoring and antiviral therapy HCMV, EBV, HSV and varicella zoster virus serological status of HSCT recipients (IgM and IgG) were determined prior to the HSCT treatment. 12 HHV-6 serology was not performed due to the lack of a reliable serology assay. All recipients and donors, except CB donors, were considered seropositive for HHV6 preceding HSCT. 13, 14 Prospectively, all HSCT patients were weekly monitored by quantitative real-time PCR for plasma viral load of EBV and HCMV during the first 4 months after HSCT. 4, [15] [16] [17] [18] [19] In retrospect, HHV6 viral load was determined in all patients from week 2 until week 6 after HSCT, as guided by the results from previous studies.
5 HHV6 types A and B are both detected by the quantitative real-time PCR assay. 20 All patients received prophylactic treatment with low-dose valacyclovir (500 mg twice daily) until at least day þ 365 after HSCT. Pre-emptive treatment for reactivation of EBV or HCMV was initiated when the plasma viral load exceeded 1000 or 500 cp/mL, respectively, based on local and international guidelines. [21] [22] [23] HCMV reactivation as well as suspicion of HCMV disease was treated with valganciclovir (900 mg orally twice daily). In case of a further increase in viral load after 14 days, foscavir (90 mg/kg i.v. twice daily) was prescribed. Plasma EBV reactivation or clinical suspicion of EBV-post-transplant lymphoproliferative disorder was treated with valacyclovir (1000 mg three times daily) and a single dose of Rituximab (375 mg/m 2 ). If possible, immunosuppressive therapy was tapered or stopped. No antiviral treatment for HHV6 reactivation was administered.
End points and definitions
Main end points. Main end point for the analyses was the development of HHV6 reactivation. With respect to HHV6 reactivation, patients were divided into two groups based on maximum HHV6 DNA load: (1) patients with no HHV6 reactivation (o1000 cp/mL) and (2) patients with HHV6 DNA load exceeding 1000 cp/mL during the follow-up period, similar to other studies. 5 A HHV6 reactivation episode was defined as 41 consecutive HHV6-positive samples. A clinically relevant viral reactivation was defined as a plasma DNA load exceeding 1000 cp/mL.
Other end points. Other end points were: time to grades 2-4 aGVHD, cGVHD and 'other viral reactivations', EFS, NRM and OS. 'Other viral reactivations' was defined as HCMV and/or EBV reactivation in a patient during follow-up. For EFS, an event was defined as progression, relapse or death. NRM was defined as all causes of mortality, except progression or relapse.
Graft failure was based on chimerism monitoring, measured by fluorescent primer-based PCR genotyping of variable-number tandem repeats. Full donor chimerism was defined as having a donor chimerism of 495%.
Statistical analysis
Analyses of the associations between the various patient characteristics and time-to-event outcomes were performed using univariate and multivariate Cox proportional hazard models. Kaplan-Meier curves were generated to illustrate survival. The duration of follow-up was the time to the last assessment for survivors. To analyze risk factors for outcomes, we considered variables associated with recipients (age, gender), the donor (donor relation, stem cell source and HLA matching) and the transplantation (indication, conditioning regimen). HLA matching was based on high-resolution typing for class I and class II Ags (10 Ags: A, B, C, DR and DQ) for BM, and PBSC donors. For CB donors, intermediate resolution criteria were used (loci A and B by intermediate resolution, and DRB1 by high-resolution typing). 24 A DPB1 mismatch was not taken into account. Identical CB grafts according to the intermediate-resolution criteria were considered as matched. For the analyses, patients were divided into a matched and mismatched group. The impact of HHV6 reactivation on aGVHD and NRM was analyzed with Cox regression analysis using HHV6 as a time-dependent covariate.
All P-values are two-sided, and a significance level a ¼ 0.05 was used. Results are expressed as hazard ratios (HR) and their corresponding 95% confidence intervals (95% CI). Statistical analysis was performed using SPSS version 15.0 (SPSS Inc, Chicago, IL, USA) and Stata version 12.0 (StataCorp, College Station, TX, USA).
RESULTS AND DISCUSSION
Patient characteristics and general results In this study, 108 patients with a median age at transplantation of 40 years (range 17-65) were included ( Table 1 ). OS at 2 years was 77%. With respect to the viral load measurements, a 495% compliance in weekly sampling after HSCT was achieved. Overall, HHV6 DNA was detected in the plasma of 18 (17%) patients, HCMV DNA in 14 (13%) patients and EBV DNA in 5 (5%) patients ( Figure 1 ). The median time to HHV6 reactivation was 18 days (range 0-35) compared with 43 days (range 4-186) for HCMV reactivation, and 35 days (range 23-92) for EBV reactivation. No differences in antiviral prophylaxis were noted between the groups with and without viral reactivation.
Main end points HHV6 reactivation was observed in 16 of the 60 (27%) patients, with MA conditioning regimen compared with 2/48 (4%) patients who received NMA conditioning regimen. The median maximum viral load for the MA group was 3826 cp/mL (1000-80 000 cp/mL), and the maximum viral load was 1000 and 13 000 cp/mL in the two NMA patients. In univariate analysis, diagnosis other than ALL/AML, CB and MA conditioning regimen were adverse prognostic factors for HHV6 reactivation. In multivariate analysis, only MA conditioning regimen remained adversely associated with HHV6 reactivation (HR ¼ 9.7; 95%CI 1.3-70.3; P ¼ 0.02, Table 2 ).
Other end points: GVHD. Overall, aGVHD was noted in 40 of the 108 (37%) patients. In univariate analysis, HHV6 reactivation, MA conditioning regimen, CB and HLA mismatch were the adverse prognostic factors for aGVHD (Table 3) . In multivariate analysis, only HHV6 reactivation remained statistically significant (HR 6.1; 95% CI 2.9-12.7; Po0.001, Table 3, Figure 2a) . cGVHD was observed in 57 of the 93 (61%) patients. HHV6 reactivation was not associated with the occurrence of cGVHD (HR 1.06, 95%CI 0.5-2.4, P ¼ 0.89).
Other viral reactivations. EBV-or HCMV reactivations were seen in 5 of the 18 (28%) patients with HHV6 reactivation compared with 14 of the 90 (16%) patients without HHV6 reactivation. In 4 of the 5 patients, the HHV6 reactivation preceded the EBV or CMV reactivation with 41 week. Patients with multiple viral reactivations did not differ between the HHV6 reactivation groups (P ¼ 0.31).
EFS, NRM and OS. Of 108 patients, 25 deceased after HSCT of whom 8 (32%) patients had HHV6 reactivation. In total, 13 of the 25 (52%) patients deceased due to GVHD, 6 (24%) due to relapse, 2 (8%) due to multiorgan failure and 4 (16%) due to acute pulmonary or cardiac disease. Of the patients with HHV6 reactivation, six died due to GVHD and two due to multiorgan failure. HHV6 reactivation and MA conditioning were adversely associated with NRM (HR ¼ 3.0 and 12.2, 95% CI ¼ 1.1-8.2 and 2.0-72, P ¼ 0.03 and 0.006, respectively). MA conditioning was associated with OS (HR ¼ 6.3, 95% CI ¼ 1.5-26, P ¼ 0.01) in multivariate analysis.
Kaplan-Meier survival curves were generated to illustrate NRM from D35 post transplant for patients without vs with HHV reactivation (landmark analysis) (see Figure 2b) .
In this study, we demonstrated that MA conditioning regimen was a strong predictor for HHV6 reactivation. Furthermore, the early HHV6 reactivation was found to be a predictor for aGVHD. These associations may have implications for HHV6 monitoring and (pre-emptive) treatment protocols.
The observed incidence of HHV6 reactivation in adults after MA conditioning regimen (16/60, 27%) was lower in comparison to the reported incidence in children (45%, after MA conditioning regimen only). 4 Very recently, Dulery et al. 6 showed high incidence of HHV6 reactivation in adults after (MA) HSCT (48%). Others noted higher incidences of HHV6 reactivation: Zerr et al. 7 performed a prospective study among 110 adult patients treated with HSCT, in which 47% of the patients had a HHV6 reactivation, 5 and Hentrich et al. 25 found that 42% of 228 patients showed HHV6 reactivation. Differences in incidences between studies might be due to a lack in standardized HHV6 diagnostic assays. 20 Standardization of HHV6 detection assays is warranted to allow the comparison of results between different laboratories to elucidate the clinical role of HHV6 viral load.
Recently, chromosomally integrated HHV6 have been found to be a cause of HHV6 DNA load positivity. 26, 27 Owing to the lack of material, we were not able to test patients and donor material prior to HSCT; however, persistent high levels of HHV6 DNA loads were not observed in this study.
Furthermore, differences between studies might be explained by the stem cell source used in adult HSCT. CB contains relatively Acute leukemia was defined as indications: AML and ALL; other was defined as multiple myeloma, CML, MDS, NHL and SAA. more naive T cells and absence of adoptive immunity, whereas BM or stimulated PBSCs contains relatively more effector memory T cells. The fact that HHV6 reactivation was more often seen after CBT has been described by others as well. [28] [29] [30] [31] Moreover in our study, three of the five adults transplanted with CB in our study developed HHV6 reactivation.
Additionally, differences in incidences between studies might be due to differences in conditioning intensity prior to HSCT, as found in our study. In the study by Zerr et al., 5 with a HHV6 reactivation incidence of 47%, no further analysis among conditioning regimens' groups was performed. The difference in incidence of HHV6 reactivation between patients receiving an MA or NMA conditioning regimen might be explained by the remaining recipient immunity after NMA conditioning regimen. NMA conditioning regimens resulted in decreased immediate procedural mortality, but residual recipient immunity is not fully ablated, as observed by various studies. Donor myeloid chimerism gradually supplants recipient hematopoiesis and full donor chimerism is delayed, compared with MA conditioning. 32 However, in contrast to the occurrence of HHV6 reactivation, the incidence of EBV-and HCMVreactivations, occurring B2 weeks later, did not differ among conditioning groups (P ¼ 0.51, data not shown). HHV6 reactivation occurred early and before the occurrence of aGVHD, and thus before the initiation of immunosuppressive treatment, whereas the majority of EBV and HCMV reactivations (63%) occurred during aGVHD treatment (median interval for GVHD and EBV/HCMV reactivation 9 days, range 0-38, data not shown). Very recently, Dulery et al. 6 confirmed these data and observed frequent HHV6 reactivation after MA conditioning prior to aGVHD treatment.
In line with our results, Dulery et al. 6 and Zerr et al. 7 described that HHV6 reactivation was associated with moderate to severe aGVHD (grades 2-4) and higher mortality rates. [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] 24, 25, [28] [29] [30] [31] [33] [34] [35] [36] [37] [38] [39] Hentrich et al. 25 reported a similar association between HHV6 reactivation and aGVHD, although no association was found between HHV6 reactivation and mortality. The association of HHV6 reactivation and aGVHD in the current study is comparable to the association found in other studies. 4, 6, 7, 25, 33, 34 Although the exact mechanism of developing aGVHD is unknown, it is thought to be triggered by tissue damage due to previous therapy (toxicity) underlying disease and conditioning regimens. 35, 36 HHV6 might be a factor in enhancing tissue damage by inflammatory responses, which is also suggested for other viruses. 2, 3, 37, 38, 40 In line with previous studies, we confirmed that HHV6 reactivation was associated with decreased EFS. [5] [6] [7] 39 This is probably caused by the high incidence of aGVHD (up to 37% in this study) after HHV6 reactivation.
Given the absence of antiviral drugs proven to be clinically effective against HHV6, prophylactic or pre-emptive treatment protocols for HHV6 reactivation are not available. Treatment with foscavir is initiated only when clinical symptoms, suspected to be associated with HHV6, are observed. It is tempting to speculate that if an effective antiviral drug for HHV-6 was available, prophylaxis may prevent reactivation and associated aGVHD. HHV6 reactivation might be a trigger or an early marker of aGVHD and therefore, although paradoxally, increasing immunosuppressive therapy during HHV6 reactivation may prevent or diminish aGVHD. Anticipating the occurrence of aGVHD (437% developed grades 2-4 aGVHD) after HHV6 reactivation, increasing the immunosuppressive therapy during HHV6 reactivation may decrease the incidence of severe aGVHD, resulting in a decrease of the cumulative immunosuppressive therapy administered to these patients.
In conclusion, an MA conditioning regimen is a strong predictor for HHV6 reactivation after HSCT in adults. HHV6 reactivation is associated with severe aGVHD (grades 2-4) and poor survival, mainly due to higher NRM. Further elucidation of the role of HHV6 reactivation after HSCT is needed. Development of HHV6-specific prophylactic antiviral and/or cellular strategies may improve the outcomes of MA-treated HSCT patients.
